Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Multicenter, 2-part, multiple-dose study designed to evaluate the safety and effectiveness of
weekly administration of panitumumab in subjects with renal carcinoma. Part 1 was initiated
in 2001 and will not be presented here. Part 2 was designed to examine a dose of 2.5 mg/kg/wk
in 2 cohorts.